[Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].
The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated.


METHODS
open, non-controlled surveillance study conducted at 744 centers.


METHODS
3,076 patients suffering from bronchitis.


METHODS
600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose.


METHODS
evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.


RESULTS
impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).


CONCLUSIONS
treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.
Gerards
H H
HH
Inpharzam GmbH, Gräfelfing.
Vits
U
U
D000111:Acetylcysteine / Q000008:administration & dosage*; D000284:Administration, Oral; D001991:Bronchitis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
D000111:Acetylcysteine
Therapie der Bronchitis. Erfolgreiche Behandlung mit N-Acetylcystein als Einmalgabe, Ergebnisse einer Anwendungsbeobachtung bei 3,076 Patienten.